The research included a cohort of CRC patients who underwent oxaliplatin‐based first‐line chemotherapy, revealing that circ‐HIPK3 expression was higher in patients with stable or progressing disease compared to those with a full or partial response. Here, HIPK3 is linked to colorectal carcinoma.